These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 387069)

  • 41. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial.
    Harada T; Momoeda M; Taketani Y; Hoshiai H; Terakawa N
    Fertil Steril; 2008 Nov; 90(5):1583-8. PubMed ID: 18164001
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A clinical overview of a new triphasic contraceptive containing gestodene.
    Christie T
    Int J Fertil; 1989 Sep; 34 Suppl():40-9. PubMed ID: 2576257
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effects of oestrogens and progesterone on oestrogen receptors in female rat liver.
    Marr W; Elder MG; Lim L
    Biochem J; 1980 Sep; 190(3):563-70. PubMed ID: 7470070
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biphasic versus monophasic oral contraceptives for contraception.
    Van Vliet H; Grimes DA; Helmerhorst F; Schulz K
    Cochrane Database Syst Rev; 2001; (2):CD002032. PubMed ID: 11406026
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect on blood coagulation and fibrinolysis in women using norethisterone or a combination of ethinyloestradiol and quingestianol.
    Korsan-Bengtsen K; Larsson B
    Gynecol Obstet Invest; 1978; 9(6):312-8. PubMed ID: 754993
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Body mass index does not affect the efficacy or bleeding profile during use of an ultra-low-dose combined oral contraceptive.
    Nakajima ST; Pappadakis J; Archer DF
    Contraception; 2016 Jan; 93(1):52-7. PubMed ID: 26410176
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The current status of oral contraceptive clinical development in Japan.
    Kuwabara Y
    Int J Fertil; 1989; 34 Suppl():18-20. PubMed ID: 2576251
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of megestrol acetate and ethinyl estradiol as an oral contraceptive.
    Echt CR; Berner HW; Dersch DM
    Fertil Steril; 1967; 18(6):840-4. PubMed ID: 6073934
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-microgram oestrogen preparations.
    Meade TW; Greenberg G; Thompson SG
    Br Med J; 1980 May; 280(6224):1157-61. PubMed ID: 7388443
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The incidence of side-effects with a low-oestrogen contraceptive pill.
    Boffa PS
    Practitioner; 1971 Feb; 206(232):263-5. PubMed ID: 5554563
    [No Abstract]   [Full Text] [Related]  

  • 51. Comparative studies on two combination oral contraceptives, one containing synthetic estrogen, the other "natural" estrogens.
    Saunders DM; Shuter B; Shearman RP
    Contraception; 1978 Nov; 18(5):527-34. PubMed ID: 729378
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical and endocrine effects of long-term hormonal contraception.
    Balogh A
    Acta Med Hung; 1986; 43(2):97-102. PubMed ID: 3588164
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metabolic effects of oral contraceptives containing 30 micrograms and 50 micrograms of oestrogen.
    Nash AL; Cornish EJ; Hain R
    Med J Aust; 1979 Sep; 2(6):277-81. PubMed ID: 230411
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Results of planned in-vitro fertilization programming through the pre-administration of the oestrogen-progesterone combined pill.
    Cohen J; Debache C; Solal P; Serkine AM; Achard B; Boujenah A; Pez JP; Paris X; Robert J; Loffredo V
    Hum Reprod; 1987 Jan; 2(1):7-9. PubMed ID: 3106405
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical assessment of a low-oestrogen combined oral contraceptive.
    Bye PG; Elstein M
    Br Med J; 1973 May; 2(5863):389-92. PubMed ID: 4574044
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prospective study of carbohydrate metabolism in women using a triphasic oral contraceptive containing norethindrone and ethinyl estradiol for 3 months.
    Spellacy WN; Ellingson AB; Kotlik A; Tsibris JC
    Am J Obstet Gynecol; 1988 Oct; 159(4):877-9. PubMed ID: 3052079
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Progress in oral contraception. Advantages of a levonorgestrel-containing 3-stage preparation over low-dose levonorgestrel and desogestrel containing monophasic combination preparations].
    Lachnit-Fixson U
    Fortschr Med; 1984 Sep; 102(33):825-30. PubMed ID: 6383993
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oestrogen treatment for increased bleeding in Norplant users: preliminary results.
    Witjaksono J; Lau TM; Affandi B; Rogers PA
    Hum Reprod; 1996 Oct; 11 Suppl 2():109-14. PubMed ID: 8982752
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of low-dose oral contraceptives on carbohydrate and lipid metabolism in women with recent gestational diabetes: results of a controlled, randomized, prospective study.
    Kjos SL; Shoupe D; Douyan S; Friedman RL; Bernstein GS; Mestman JH; Mishell DR
    Am J Obstet Gynecol; 1990 Dec; 163(6 Pt 1):1822-7. PubMed ID: 2256489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.